Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | MTOR | P42345 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | TP53 | P04637 | 2/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.62 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.62 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.62 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.62 |
| ▸ | GMNN | O75496 | 1/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.62 |
| ▸ | THPO | P40225 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | BLM | P54132 | 1/20 | 0.62 |
| ▸ | HBB | P68871 | 1/20 | 0.62 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.62 |
| ▸ | PYGM | P11217 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | CDA | P32320 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2584289 | 1.00 | LMNA (0.62) | LMNAMTORALDH1A1TP53THRB | |
| SCHEMBL114751 | 1.00 | LMNA (0.62) | LMNAMTORALDH1A1TP53THRB | |
| SCHEMBL28067693 | 0.93 | LMNA (0.55) | LMNAMTORALDH1A1TP53THRB | |
| SCHEMBL11207773 | 0.90 | LMNA (0.50) | LMNAMTORALDH1A1TP53THRB | |
| SCHEMBL2580878 | 0.90 | LMNA (0.50) | LMNAMTORALDH1A1TP53THRB | |
| SCHEMBL11207095 | 0.89 | LMNA (0.49) | LMNAMTORALDH1A1TP53THRB | |
| SCHEMBL6722527 | 0.89 | PDE2A (0.50) | LMNAMTORALDH1A1TP53THRB | |
| SCHEMBL369266 | 0.89 | PDE2A (0.50) | LMNAMTORALDH1A1TP53THRB | |
| SCHEMBL13908141 | 0.89 | PDE2A (0.50) | LMNAMTORALDH1A1TP53THRB | |
| Hydrochloric Acid SCHEMBL10885537 | 0.89 | LMNA (0.49) | LMNAMTORALDH1A1TP53THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1792 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263678-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | REJUVENATION TECHNOLOGIES, INC. (US) | 2025-08-21 | — | — | US | claimed |
| EP-4601695-A2 | MRNA THERAPEUTIC COMPOSITIONS | Nutcracker Therapeutics, Inc. (US) | 2025-08-20 | — | — | EP | claimed |
| US-12357664-B2 | Optimized oncolytic viruses and uses thereof | SATOR THERAPEUTICS (US) | 2025-07-15 | — | — | US | claimed |
| US-12343420-B2 | Stabilized polyribonucleotide coding for an elastic fibrous protein | EBERHARD KARLS UNIVERSITAET TUEBINGEN MEDIZINISCHE FAKULTAET (DE) | 2025-07-01 | — | — | US | claimed |
| CN-120025389-A | Phosphoramidate nucleoside drug compound, and synthetic method and drug application thereof | 河南师范大学 | 2025-05-23 | — | — | CN | claimed |
| US-20250121046-A1 | MRNA THERAPEUTIC COMPOSITIONS | NUTCRACKER THERAPEUTICS, INC. | 2025-04-17 | — | — | US | claimed |
| US-20250082742-A1 | MRNA THERAPEUTIC COMPOSITIONS | MEDICI THERAPEUTICS, INC. | 2025-03-13 | — | — | US | claimed |
| WO-2025024123-A1 | NOVEL CITICOLINE DERIVATIVES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-01-30 | — | — | WO | claimed |
| CN-118978559-A | Synthesis method and medicinal application of phosphoramidate nucleoside prodrug | 河南师范大学 | 2024-11-19 | — | — | CN | claimed |
| EP-4379052-A2 | MRNA PURIFICATION BY TANGENTIAL FLOW FILTRATION | Ethris GmbH (DE) | 2024-06-05 | — | — | EP | claimed |
| EP-0983290-A1 | METHOD FOR PRODUCING POLYMERS HAVING NUCLEO-BASES AS SIDE-GROUPS | Morphochem AG (DE) | 2000-03-08 | — | — | EP | claimed |
| US-6020483-A | Nucleoside modifications by palladium catalyzed methods | NEXSTAR PHARMACEUTICALS, INC. (US) | 2000-02-01 | — | — | US | claimed |
| EP-0948256-A1 | INDUCTION OF VIRAL MUTATION BY INCORPORATION OF MISCODING RIBONUCLEOSIDE ANALOGS INTO VIRAL RNA | THE UNIVERSITY OF WASHINGTON (US) | 1999-10-13 | — | — | EP | claimed |
| EP-0914324-A2 | SPECIFIC INHIBITORS OF DNA METHYLTRANSFERASE ENZYME | McGILL UNIVERSITY (CA) | 1999-05-12 | — | — | EP | claimed |
| WO-1998051697-A2 | METHOD FOR PRODUCING POLYMERS HAVING NUCLEO-BASES AS SIDE-GROUPS | MORPHOCHEM AG (DE) | 1998-11-19 | — | — | WO | claimed |
| WO-1998018324-A1 | INDUCTION OF VIRAL MUTATION BY INCORPORATION OF MISCODING RIBONUCLEOSIDE ANALOGS INTO VIRAL RNA | THE UNIVERSITY OF WASHINGTON (US) | 1998-05-07 | — | — | WO | claimed |
| EP-0828750-A1 | PALLADIUM CATALYZED NUCLEOSIDE MODIFICATION METHODS USING NUCLEOPHILES AND CARBON MONOXIDE | NeXstar Pharmaceuticals, Inc. (US) | 1998-03-18 | — | — | EP | claimed |
| WO-1997044346-A2 | SPECIFIC INHIBITORS OF DNA METHYLTRANSFERASE ENZYME | MCGILL UNIVERSITY (CA) | 1997-11-27 | — | — | WO | claimed |
| WO-1996038460-A1 | PALLADIUM CATALYZED NUCLEOSIDE MODIFICATION METHODS USING NUCLEOPHILES AND CARBON MONOXIDE | NEXSTAR PHARMACEUTICALS, INC. (US) | 1996-12-05 | — | — | WO | claimed |
| EP-0653439-A2 | Stabilized oligonucleotids and the use thereof | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-05-17 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250121046-A1 | MRNA THERAPEUTIC COMPOSITIONS | RNMT, RNGTT, NSUN3 | LMNA 3363/4885MTOR 4385/4885ALDH1A1 3114/4885 |
| US-20250263678-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | RNASE1, POLRMT, TERT | LMNA 233/4885MTOR 4147/4885ALDH1A1 2668/4885 |
| US-20250082742-A1 | MRNA THERAPEUTIC COMPOSITIONS | RNMT, RNGTT, NSUN3 | LMNA 3363/4885MTOR 4385/4885ALDH1A1 3114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.